Tenaya - TNYA Enterprise Value-to-Revenue Multiple

Tenaya (TNYA) - corporate logo

Tenaya Therapeutics (TNYA) is valued as an authoritative scientific hub in the field of gene therapy. Diversification of research across various molecular pathways minimizes the risk of trial failures. Changes in the EV/Sales valuation demonstrate the business value dynamics, where the 1349.83 level reflects the current magnitude of the metric. Additionally, the company complies with environmental regulations by implementing energy saving and emission filtration in its laboratories.

Tenaya Therapeutics - TNYA EV/Sales Multiple (period 11/23/2025 - 11/20/2026)

Tenaya Therapeutics Inc - analytical breakdowns and key metrics (TNYA)

- issuer market value details:
Fundamental valuation:TNYA - Tenaya Therapeutics
Brand item of Tenaya

The EV/Sales multiple combines market capitalization and net debt, providing an immediate market reaction to shifting revenue expectations. This indicator captures the investor consensus regarding the business value, stripped of its debt load. For Tenaya Therapeutics (TNYA), this calculation accounts for capital expenditures related to laboratory greening and the implementation of energy-saving measures. An increase in this value signals capitalization potential. By analyzing changes in the EV/Sales multiple, one can assess the risk of asset overvaluation.